Developing the next generation of bead-based bioassays, which employ mass spectrometry and optical imaging to facilitate high information content proteomic research.
Vladislav Bergo, CEO
Developing advanced neuorostimulation products and neuromodulation technologies that reduce device failure rates and improved efficacy over time.
Larry Derose, CEO; Barry Yomtov, CTO
Cellanyx Diagnostics LLC www.cellanyx.com
Developing in vitro tissue and cell culturing techniques for use in research and in vitro diagnostics, specifically prognostic information for prostate cancer treatment decisions.
Ashok Chander,CEO; Mani Foroohar,CSO
Cell Assay Innovations, Inc. www.cellassayinnov.com
A biotechnology service company dedicated to cell-based assay technology development with a focus on proprietary kinase assay panels for drug screening and other cell culture services.
Deborah Moshinsky, President; LiPing Wu, CSO
GlobalBio, Inc. www.globalbioinc.com
An antibody engineering company developing faster and more efficient methods for the discovery and optimization of antibodies for therapeutic settings.
Juan Carlos Almagro, PhD, Founder
Offers pharmaceutical and biotech companies reliable and efficient access to small molecule metabolites in order to accelerate drug R&D and reduce costs.
Marc Bazin, President; Ryan Buzdygon, Director of Operations
Developing a neurostimulator device to mitigate insomnia.
Peter Kelley, Founder; John Douglas, Consultant
IVIVA Medical, Inc. (website under construction)
Developing bioengineered autologous dialysis grafts, an “implantable artificial kindney,” to substitute for, augment, or replace human kidney function without hemodialysis or the need for immunosuspression.
Harold Ott, MD, President & CEO; Charles Klassen, Research Scientist
Lariat Biosciences (website under construction)
Developing a non‐invasive diagnostic to detect early signs of cancer based on circulating DNA fragments arising from the death of tumor cells which carry the mutant genetic signature that gave rise to the abnormal growth.
Jonathan Larson, CEO
Lighthouse Proteomics, LLC www.lighthouseproteomics.com
Lighthouse Proteomics offers advanced proteomic services and expertise to identify, characterize, and quantify proteins to support research and development for the biotech and pharmaceutical industry and academia.
Jeff Silva, CEO; Manor Askenazi, Director of Informatics
MCC Global Laboratories, Inc. www.mccgloballabs.com
Develops, manufactures, and distributes innovative surface biological decontamination technology to a worldwide healthcare, life sciences, and biodefense market.
Loutfi Kachou, Dan Bandar, Gina Bandar-Kachou
MiMecore Therapeutics LLC www.mimecore.com
Developing a novel suite of engineered proteoglycan-mimics designed to assist in the healing and restoration of soft tissue extracellular matrix compromised by age, injury or medical disorder.
Vince Novak, CEO & Founder; Gene Skrabut, VP Research; Tom Jozefiak, VP Science & Technology
RAN Biotechnologies, Inc. www.ranbiotechnologies.com
Designs and manufacture two types of materials: (1) Solid Resins for selective capture and controlled release of viruses, bacteria, and proteins. Examples of related applications are viral clearance, vaccine purification, fluid disinfection and diagnostics; (2) FluoroSurfactants for droplet microfluidics.
Roger Nassar, CEO
seqWell, Inc. www.seqwell.com
Offers a DNA sequencing service called kiloSEQ ™, based on novel and proprietary technology that will enable high-quality, long-read sequencing of plasmids and amplicons for development of therapeutic biologicals and synthetic biology applications.
Joseph Mellor, CEO; Jack Leonard, Head of Operations
Thrive Bioscience, Inc. www.thrivebio.com
Is developing Smart Incubation Systems™ that will automatically monitor, maintain, passage, and assay cell and tissue culture.
Alan Blanchard, CSO; Thomas Farb, COO/CFO; Brian Foley, VP of Engineering & Manufacturing
TriBiotica’s proprietary technology uses the tumor’s unique genetic signature to force the tumor cells to assemble novel immune targets that would not be naturally produced, but which allows specific elimination of tumor cells
Jim Kurnick, MD, Chairman; Matt Lawlor, President; Ian Dunn, CTO; Estelle Newton